International Edition
Latest News
Health

Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Deal

Rosemont Pharmaceuticals announced on Monday that it has entered into a definitive merger agreement to acquire Aytu BioPharma for $2.70 per share in an all-cash deal. The transaction, which involves an all-cash offer of $2.70 per share, aims…

Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Deal

Rosemont Pharmaceuticals announced on Monday that it has entered into a definitive merger agreement to acquire Aytu BioPharma for $2.70 per share in an all-cash deal.

The transaction, which involves an all-cash offer of $2.70 per share, aims to expand the UK-based company’s presence in the United States specialty pharmaceutical market.

The agreement includes an established portfolio of ADHD treatments and an emerging asset for Major Depressive Disorder (MDD). Rosemont, which is backed by the private equity firm Inflexion, expects the acquisition to combine its expertise in oral liquid medicines with Aytu’s commercial capabilities in central nervous system (CNS) diseases.

“The proposed acquisition of Aytu marks an important step in Rosemont’s US growth strategy,” said Alok Sonig, CEO of Rosemont Pharmaceuticals. “Together with Rosemont’s product development, regulatory, manufacturing and commercial expertise, we believe we can build a strong platform for future growth.”

The deal has received unanimous approval from the Aytu board of directors. According to Aytu CEO Josh Disbrow, the agreement reflects the company’s progress in building its CNS and pediatric portfolio. “We see a strong strategic fit between our portfolio and Rosemont’s experience developing and commercializing specialty medicines,” Disbrow said.

Rosemont plans to initiate a tender offer to acquire all outstanding shares of Aytu common stock within 10 business days. Following the successful completion of the tender offer, the company intends to acquire any remaining shares through a second-step merger at the same $2.70 per share price.

The transaction is subject to customary closing conditions, including the tender of a majority of Aytu’s outstanding shares and the resolution of certain outstanding warrants. Both companies anticipate the deal will close in late December 2026. Until that time, Rosemont and Aytu will continue to operate as independent entities.

Aytu’s executive officers, directors, and certain stockholders affiliated with Nantahala Capital Management and Stonepine Capital Management have signed tender and support agreements.

What does the acquisition mean for current Aytu patients? Rosemont said that a key priority following the completion of the deal is maintaining continuity of supply and service for customers and partners.

What is the role of Inflexion in this deal?
Rosemont Pharmaceuticals is backed by Inflexion, a European private equity firm with $21 billion in assets under management. Inflexion established a dedicated team in New York City in 2025 to support growth in the US market.

Are there any regulatory hurdles remaining?
The transaction remains subject to the satisfaction or waiver of conditions outlined in the tender offer, including the tender of a majority of outstanding shares. Rosemont and Aytu have filed or will file necessary documentation with the Securities and Exchange Commission, including a Schedule TO and a Schedule 14D-9, to provide shareholders with further details regarding the process.

About the author: Dr Natalie Singh - Health Editor

Board‑certified internal‑medicine physician and MPH. Natalie authored peer‑reviewed studies on infectious disease and served as medical editor. “Dr. Natalie Singh delivers evidence‑based health news, medical breakthroughs, and expert wellness guidance.”